The COVID-19 Pandemic – Multimedia

This eBook highlights innovative purification tools that support scientists in the production of high-quality mRNA for therapeutic applications.

In this interview, Dr. Katalin Karikó talks about discovering she had won the Nobel Prize for discoveries that accelerated the introduction of vaccines for COVID-19. She recalls her journey and some of the setbacks on the path to the mRNA vaccines.

Each of your molecular or immunoassay development projects is unique. So, you need solutions tailored to your specific needs.

For over 150 years, wastewater has provided a rich source of data for tracking infectious diseases and informing public health decisions. Since the COVID-19 pandemic, the scope for wastewater-based epidemiology (WBE) has increased significantly and requires increasingly rapid, versatile and accurate detection methods to monitor the spread of disease.

Women are at a slightly higher risk of having a heavier period after COVID vaccination, a study finds.

Speaking at the Vaccine Research & Development 2022 online symposium, Nikolai Petrovsky, Professor of Medicine at FLinder's University, delivered his talk on the first Australian-developed vaccine in over 40 years.

Simulations show that the proteins on the influenza viral surface targeted by vaccines can tilt and wave in “breath-like” motions, which could be exploited to better defend against the flu.

In a normal immune response, entry of the SARS-CoV-2 virus into lung tissue induces controlled activation of the immune system.

In this infographic, we explore what is meant by disease modeling and highlight how advanced cell models are helping researchers to overcome some of the limitations associated with classical cell lines and animal models.

Oligonucleotide therapeutics are short DNA or RNA molecules that modulate the expression of target RNA for the treatment of diseases. The success of mRNA-based COVID-19 vaccines has brought renewed interest to other nucleic acid drugs, and the oligo therapeutics market is expected to grow by 25–30% in the next five years with over 1,000 oligonucleotide molecules currently in the pipeline.